ArticleJournal of the National Cancer Institute2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

William V Padula et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.